Cargando…

Clinical Correlates and Outcome of Major Depressive Disorder and Comorbid Migraine: A Report of the European Group for the Study of Resistant Depression

BACKGROUND: The present multicenter study aimed at defining the clinical profile of patients with major depressive disorder (MDD) and comorbid migraine. METHODS: Demographic and clinical information for 1410 MDD patients with vs without concurrent migraine were compared by descriptive statistics, an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fugger, Gernot, Dold, Markus, Bartova, Lucie, Mitschek, Marleen M M, Souery, Daniel, Mendlewicz, Julien, Serretti, Alessandro, Zohar, Joseph, Montgomery, Stuart, Fabbri, Chiara, Frey, Richard, Kasper, Siegfried
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7710912/ https://www.ncbi.nlm.nih.gov/pubmed/32885810 http://dx.doi.org/10.1093/ijnp/pyaa035

Ejemplares similares

Sex‐related effects in major depressive disorder: Results of the European Group for the Study of Resistant Depression
por: Bartova, Lucie, et al.
Publicado: (2021)

Psychotherapy employed additionally to Psychopharmacotherapy is not related to Better Treatment Outcome in Major Depressive Disorder
por: Bartova, L., et al.
Publicado: (2022)

The Choice of Either Quetiapine or Aripiprazole as Augmentation Treatment in a European Naturalistic Sample of Patients With Major Depressive Disorder
por: Bartova, Lucie, et al.
Publicado: (2021)

Age as a moderating factor of treatment resistance in depression
por: Kautzky, Alexander, et al.
Publicado: (2023)

Major Depression and the Degree of Suicidality: Results of the European Group for the Study of Resistant Depression (GSRD)
por: Dold, Markus, et al.
Publicado: (2018)

The sociodemographic and clinical profile of patients with major depressive disorder receiving SSRIs as first-line antidepressant treatment in European countries
por: Fugger, Gernot, et al.
Publicado: (2022)

PS75. Psychopharmacoepidemiology of Major Depressive Disorder in European Tertiary Psychiatric Treatment Centers
por: Bartova, Lucie, et al.
Publicado: (2016)

Clinical correlates of augmentation/combination treatment strategies in major depressive disorder
por: Dold, M., et al.
Publicado: (2018)

Clinical factors predicting treatment resistant depression: affirmative results from the European multicenter study
por: Kautzky, A., et al.
Publicado: (2018)

The Genetics of Treatment-Resistant Depression: A Critical Review and Future Perspectives
por: Fabbri, Chiara, et al.
Publicado: (2018)

Body mass index and clinical outcomes in individuals with major depressive disorder: Findings from the GSRD European Multicenter Database
por: Kraus, Christoph, et al.
Publicado: (2023)

Silexan for treatment of anxiety and depression in the context of COVID-19
por: Bartova, Lucie, et al.
Publicado: (2023)

The Impact of BDNF Polymorphisms on Suicidality in Treatment-Resistant Major Depressive Disorder: A European Multicenter Study
por: Schosser, Alexandra, et al.
Publicado: (2017)

PS87. An update on prediction of treatment outcome in treatment resistant depression
por: Kautzky, Alexander, et al.
Publicado: (2016)

Dimensions of Delusions in Major Depression: Socio-demographic and Clinical Correlates in an Unipolar-Bipolar Sample
por: Zaninotto, Leonardo, et al.
Publicado: (2015)

A polygenic predictor of treatment-resistant depression using whole exome sequencing and genome-wide genotyping
por: Fabbri, Chiara, et al.
Publicado: (2020)

Treatment Response of Add-On Esketamine Nasal Spray in Resistant Major Depression in Relation to Add-On Second-Generation Antipsychotic Treatment
por: Dold, Markus, et al.
Publicado: (2020)

Polygenic risk scores for neuropsychiatric, inflammatory, and cardio‐metabolic traits highlight possible genetic overlap with suicide attempt and treatment‐emergent suicidal ideation
por: Fanelli, Giuseppe, et al.
Publicado: (2022)

Beneficial effects of Silexan on co-occurring depressive symptoms in patients with subthreshold anxiety and anxiety disorders: randomized, placebo-controlled trials revisited
por: Bartova, Lucie, et al.
Publicado: (2022)

Towards achieving remission in the treatment of depression
por: Mendlewicz, Julien
Publicado: (2008)

Silexan for treatment of psychiatric manifestations in the context of COVID-19: a case series
por: Bartova, L., et al.
Publicado: (2023)

The exploration of mechanisms of comorbidity between migraine and depression
por: Zhang, Qing, et al.
Publicado: (2019)

Mechanische Schutzfixierung – Herausforderungen und Management: Fallvignetten aus der psychiatrischen Intermediate Care Station der Wiener Universitätsklinik
por: Popper, Valentin, et al.
Publicado: (2021)

Migraine With Comorbid Depression: Pathogenesis, Clinical Implications, and Treatment
por: Asif, Nailah, et al.
Publicado: (2022)

Genetics and major depressive disorder: clinical implications for disease risk, prognosis and treatment
por: Fabbri, Chiara, et al.
Publicado: (2020)

Exploration of intrinsic brain activity in migraine with and without comorbid depression
por: Ma, Mengmeng, et al.
Publicado: (2018)

Pharmacogenetics and Depression: A Critical Perspective
por: Corponi, Filippo, et al.
Publicado: (2019)

Genetics of Treatment Outcomes in Major Depressive Disorder: Present and Future
por: Fabbri, Chiara, et al.
Publicado: (2020)

Efficacy of Silexan in patients with anxiety disorders: a meta-analysis of randomized, placebo-controlled trials
por: Dold, Markus, et al.
Publicado: (2023)

Healthcare Expenditures Associated With Comorbid Anxiety and Depression Among Adults With Migraine
por: Alwhaibi, Monira, et al.
Publicado: (2021)

Depressive symptoms and neuroticism-related traits are the main factors associated with wellbeing independent of the history of lifetime depression in the UK Biobank
por: Fabbri, Chiara, et al.
Publicado: (2023)

Transcriptome-wide association study of treatment-resistant depression and depression subtypes for drug repurposing
por: Fabbri, Chiara, et al.
Publicado: (2021)

Anhedonia and Depressive Disorders
por: Serretti, Alessandro
Publicado: (2023)

Combining machine learning algorithms for prediction of antidepressant treatment response
por: Kautzky, Alexander, et al.
Publicado: (2020)

How to Utilize Clinical and Genetic Information for Personalized Treatment of Major Depressive Disorder: Step by Step Strategic Approach
por: Fabbri, Chiara, et al.
Publicado: (2020)

Possible Modulatory Role of ARC Gene Variants in Mood Disorders
por: Crisafulli, Concetta, et al.
Publicado: (2021)

Effects of onabotulinumtoxinA treatment for chronic migraine on common comorbidities including depression and anxiety
por: Blumenfeld, Andrew M, et al.
Publicado: (2019)

Identification of genetic risk loci for depression and migraine comorbidity in Han Chinese residing in Taiwan
por: Tsai, Ming-Chen, et al.
Publicado: (2023)

The contribution of stress to the comorbidity of migraine and major depression: results from a prospective cohort study
por: Swanson, Sonja A, et al.
Publicado: (2013)

High efficacy of onabotulinumtoxinA treatment in patients with comorbid migraine and depression: a meta-analysis
por: Affatato, Oreste, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_9lp8lu7r34k9fvfplc37g3qftd